ICD Pharma is developing Cannabis-based medicines, which will soon be available for patients and doctors around the world.
Our product pipeline includes Cannabis-based products in unique formulations, based on a portfolio of proprietary pharmaceutical delivery technologies, developed to address a variety of unmet clinical needs.
Based on many years of pharmaceutical development and with a track record of numerous drugs brought to market, we are creating a portfolio of best-in-class Cannabis-based therapies relying on novel formulations.
ICD Pharma's vision is to
become a global leader in development of Cannabis
based medicines for better,
more effective and patient friendly care.
What we do
• Breakthrough technologies • Improved performance
• Better patients experience
What Patients Say
"It is always a battle to give Jane the oil, she dislikes the taste and when we mixed it with yogurt and other food, we never know how much she really consumes.
I wish there was non-oily, tasty syrup that she can take with a smile"
ICD Pharma Founders
Dr. Doron Friedman
30 years of innovative formulations development.
More than 70 patents in the US/EU alone.
Expert in drug delivery systems.
Best seller products, FDA approved, selling worldwide under the leading brands including Bauch & Lomb, Bayer, Dr. Reddy's and more.
25 years of CEO and leadership experience in consumer brand and retail management around the world.
CEO/GM/founder experience: Merisent and Mafco, iDigital, Reckitt Benckiser, Unilever.
Branding expertise across consumer segments: Apple ,Nurofen, Strepsils,
Dove, Knorr, Finish, Magnum, Durex
and many more.
20 years of management and investment experience, life science
VC investments, entrepreneurship,
and big pharma.
Co-founder and board member of pharmaceutical startup companies.
Formerly a partner in Israel Healthcare Ventures (IHCV) with $200 million under management in medical device, pharma,
and biotech startups.
Formerly in McKinsey, Novartis,
D.E. Shaw & Co.